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Abstract
Objectives:We aim to study the effects of the prescription of benzodiazepines and
antidepressants on cognitive and functional decline in older adults living with Alz-
heimer's disease (AD) and Lewy body dementia (LBD) over a 5‐year follow‐up.
Methods: This is a longitudinal analysis of a Norwegian cohort study entitled “The
Dementia Study of Western Norway” (DemVest). We included 196 patients newly
diagnosed with AD (n = 111) and LBD (n = 85), followed annually for 5 years. Three
prescription groups were defined: only benzodiazepines (BZD), only antidepressants
(ADep), and the combination of benzodiazepines and antidepressants (BZD‐ADep).
Linear mixed‐effects models were conducted to analyze the effect of the defined
groups on the outcomes. The outcomes were functional decline, measured by the
Rapid Disability Rating Scale—2, and cognition measured with the Mini‐Mental
State Examination.
Results: Prescription of the combination of benzodiazepines and antidepressants in
LBD was associated with faster functional decline. In AD, the prescription of BZD
and BZD‐ADep was associated with greater functional deterioration. ADep alone
did not show positive or negative significant associations with the studied outcomes.
Conclusions: BZD and especially the combination of BZD and ADep are associated
with functional decline in AD and LBD and should be used cautiously.
K E YWORD S
activities of daily living, Alzheimer's disease, Antidepressive Agents, benzodiazepines,
cognitive decline, dementia, functional disability, hypnotics and sedatives, Lewy body dementia
Key Points
� Combination of benzodiazepines and antidepressants in Lewy body dementia was associ-
ated with faster functional decline
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� Benzodiazepines and the combination of benzodiazepines and antidepressants in Alz-
heimer's disease were associated with greater functional deterioration
� The consumption of antidepressants alone did not show positive or negative significant
associations with cognitive or functional decline
1 | INTRODUCTION:
Neurodegenerative disorders, such as dementia, are frequent chronic
diseases.1 Worldwide, around 50 million people have dementia, and
there are nearly 10million new cases every year.2 Alzheimer's disease
(AD) is the most common cause of dementia and contributes to 60%–
70% of all cases.2 Lewy body dementia (LBD) is the second most
common type of neurodegenerative dementia and is often under-
diagnosed despite showing worse prognosis than AD.3–5 Functional
decline is essential for the diagnosis of dementia and also is one of the
most important markers of progression.6 Functional status depends
on several aspects including social, demographic, and health factors.
Besides, it is related tomorbidity, mortality, and quality of life.7,8 Thus,
it has become an important measurement in the comprehensive
geriatric assessment and patient‐centered care for older adults.9
Neuropsychiatric symptoms (NPS) such as depression, anxiety,
agitation, and sleep disturbances are very common in dementia10,11
and have large consequences for quality‐of‐life, the progression of the
disease, and carer burden.12,13 Psychotropic drugs are commonly
prescribed to treat NPS, although with uncertain clinical potency and
high risk of adverse effects in older adults with dementia.14–16 Pre-
scription of such medications is still high, a recent meta‐analysis in
European nursing homes reported a frequency of use of 44.8% for
benzodiazepines (BZD) and 38.3% for antidepressants (ADep).17 In
older adults BZD prescription is associated with adverse events, such
as dizziness, syncope, falls, fractures, hospitalizations, delirium, and
increased mortality.18,19 Thus, they should be carefully managed and
preferably avoided particularly in individuals with high comorbidity,
frailty, and dementia.14 The evidence regarding the ADep benefits in
mood symptoms in people with dementia is mixed and the data are
difficult to interpret because of small sample sizes, heterogeneity, and
use of multiple outcome measures.20 But, ADep especially in older
adults could also enhance the risk of adverse events, such as falls.16,21
Despite this, long‐term prescription of BZD, alone or in combination
with another psychotropic drug such as ADep is common in clinical
practice, including in the Nordic countries.22,23 Previous publications
from our group have shown that the risk of using potentially inap-
propriate medications in older adults with dementia increases with
each medication added.24 Prior research shows that long‐term use of
BZD combined with tricyclic ADep is related to cognitive deteriora-
tion in older adults.25,26 However, the effect of BZD alone and in
combination with ADep (BZD‐ADep) on functional decline in people
with dementia has been less explored especially in people diagnosed
with LBD.
We aim to study the effects of the prescription of BZD and
ADep on cognitive and functional decline over 5 years in a mild
dementia cohort including subgroups diagnosed with AD and LBD.
2 | MATERIALS AND METHODS
2.1 | Setting and participants
This is a longitudinal analysis of a Norwegian cohort study entitled
“The Dementia Study of Western Norway” (DemVest). The DemVest
study recruited patients from dementia clinics in Hordaland and
Rogaland counties diagnosed with mild dementia. Mild dementia was
defined as aMini‐Mental Status Examination (MMSE) score≥ to 20 or
a Clinical Dementia Rating global score= 1. Herewe included patients
with AD and LBD with complete information regarding medication,
activities of daily living (ADL), and cognition, yielding a total of 196
participants (AD = 111; LBD = 85) who were followed annually. The
flow of patients during the study period is shown in Appendix 1.
Exclusion criteria were moderate or severe dementia, delirium
(four of the screened candidates were excluded due to delirium),
previous bipolar or psychotic disorder, terminal illness, or a recently
diagnosed major somatic disease, which could significantly impact
cognition, function, or study participation. Further information
regarding the DemVest study can be found elsewhere4,27,28
Dementia with Lewy bodies (DLB) and Parkinson's Disease
Dementia (PDD) groups were combined in an LBD group given
pathological and clinical similarities.6
2.2 | Assessments
Dementia Diagnosis was established according to DSM‐IV criteria
and was further classified as a specific type of dementia when
complying with corresponding validated criteria: for AD (according
to National Institute of Neurological and Communicative Disorders,
Stroke‐AD and Related Disorders Association),29 or DLB6 and PDD30
(according to the DLB 2005 consensus criteria and the Movement
Disorder Task Force). Pathological diagnosis was ascertained in 56
subjects of the DemVest cohort, providing diagnostic accuracy above
80% when clinical criteria were applied.31
2.3 | Drug‐prescription classification
Drug names and dosages at baseline were retrieved from the patient
or family members and were either given orally or based on a written
medication list. Information about over‐the‐counter drugs could not
be retrieved. Medications were classified according to the Anatomical
Therapeutic Chemical classification system (ATC).32 The psychotropic
drugs of interest were antidepressants (N06A) and benzodiazepines.
Many benzodiazepines are classified as anxiolytics (N05B) and
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hypnotics (N05C). Besides, the nonbenzodiazepine medications
(N05CF) known as “Z‐drugs” also act via GABA receptors. Thus, our
defined BZD group consisted of drugs classified in following ATC‐
groups: N05BA, N05CD, and N05CF. We established three groups as
follows: (1) Benzodiazepines (BZD), (2) Antidepressants (ADep), and
(3) combination of BZD and ADep (BZD‐ADep). Medications were
registered in baseline and yearly during the 5 years of the study.
2.4 | Functional decline in ADL
The ADL were evaluated with the first 13 items (those specifically
referring to current difficulties in ADL) from the Norwegian version
of the Rapid Disability Rating Scale‐2 (RDRS‐2).33,34 The 13 included
items were: (1) Eating, (2) Making simple food (e.g., sandwiches), (3)
Cooking dinner and adhere to a diet, (4) Mobilization—inside/outside
(with or without aids), (5) Daily personal care (including brushing
teeth, combing hair, and maintaining personal hygiene), (6) Bathing/
showering, (7) Dressing (including finding clothes), (8) Toilet usage
(including occasional clothing and cleaning), (9) Usage of telephone,
(10) Buying food and other necessary items, (11) Handling money and
paying bills, (12) Having a financial overview plan ahead and writing
tax returns, and (13) Taking medications as prescribed. Each item was
scored from 1 to 4 (Alone = 1, with some help = 2, with a lot of
help = 3 and Can Not perform = 4) and then divided over the number
of items. We summarized the total mean score of the aforementioned
items yearly, over a 5‐year follow‐up.35,36 A higher score indicates a
higher level of functional decline.
2.5 | Cognitive decline
Cognitionwas evaluated using theMMSE. Itwas assessed annually and
Its trajectorywas analyzed during the follow‐up as continue variable.37
2.6 | Other variables
Comorbidities at baseline were assessed retrospectively using the
Cumulative Illness Rating Scale (CIRS), a systematic scale of
comorbidity (higher value indicates more/higher comorbidities).38
Comorbidities were registered based on patient and informant
reports. The validated Norwegian Neuropsychiatric Inventory (NPI)
was used to interview family or caregivers, and the nursing home
version (NPI‐Nursing Home) was used after participants were
admitted to nursing homes.39,40 All assessments were completed by
the informant who had the most day‐to‐day contact with the patient.
The 12 domains of NPI were registered as present or not during the
past 4 weeks, and if present, scored according to their frequency 1–4
and severity 1–3 was registered. Here, we report the frequency �
severity score for the domains.We estimated the frequency� severity
score at the time of diagnosis and its longitudinal course for 5 years.
2.7 | Statistical analysis
A descriptive analysis was performed by estimating percentages for
categorical variables and means and standard deviations for quan-
titative variables. Random coefficient mixed models were used to
analyze the potential longitudinal association of the consumption of
BZD and ADep with cognitive and functional decline for (a) AD
patients, (b) LBD patients, and (c) all patients. For longitudinal
trajectories of decline, time was used in its linear and quadratic
forms. The random effects were an intercept and a slope for time to
each subject in the study, assuming an unstructured covariance
matrix. Time was centered at 3 years, and the rest of the variables
were centered at their mean on the baseline. For model selection,
Bayesian Information Criterion (BIC) was used, and variables
significance was carried out at 0.05. The model for ADL prediction
was adjusted for age, sex, comorbidities at baseline (CIRS), and
MMSE. The model for MMSE prediction was adjusted by the same
variables, and ADL in place of MMSE. Since BZD and ADep are
likely used to treat NPS, and these symptoms may lead to
worsening cognition and function by themselves, we adjusted for
NPS using the NPI.41 We show unadjusted and adjusted models
results. MMSE was treated as a left‐ and right‐censored variable,
and corrected by a Tobit linear mixed effect model. Statistical
analyses were performed using STATA 15®.
3 | RESULTS
The descriptive information of the sample can be found in Table 1.
The AD and LBD groups did not differ significantly concerning age or
MMSE, but the CIRS and NPI scores were significantly higher in the
LBD group compared to AD. At baseline, 6.6% were prescribed BZD
alone, 24.5% ADep alone, and 9.7% the combination. Figure 1 shows
the prescription curves for the three studied groups during the 5
years' follow‐up.
3.1 | Functional decline
As expected, both AD and LBD showed functional decline during
the observation period. Table 2 displays the results of the linear
mixed models conducted. After adjustments, in the LBD group,
BZD‐ADep was associated with faster functional decline (Est.
0.251 SE 0.089 p‐value 0.005). For the AD group, faster functional
deterioration was associated with BZD prescription alone (Est.
0.226 SE 0.087 p‐value 0.009) and BZD‐ADep (Est. 0.165 SE
0.058 p‐value 0.005). Likewise, for the total sample, greater
functional deterioration was associated with BZD prescription
alone (Est. 0.142 SE 0.066 p‐value 0.032, significant in the AD
group only) and BZD‐ADep (Est. 0.218 SE 0.049 p‐value <0.0001).
Predicted trajectories of functional decline can be visualized in
Figure 2.
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3.2 | Cognitive decline
The MMSE score declined in both patient groups during the study
period. After adjusting for possible confounders, there were no sig-
nificant associations between the prescription groups and cognition
(Table 3).
4 | DISCUSSION
In this study, we found that the prescription of BZD in combination
with ADep was associated with a faster functional decline in patients
with AD and LBD during a 5‐year follow‐up. The effect was relatively
small but statistically significant. Little has been reported regarding
functional prognosis in people diagnosed with dementia, especially in
those diagnosed with LBD.18
In general, compared with the young, older adults are more sen-
sitive to BZD, including a higher risk for confusion and disorientation.
This increased sensitivity is directly related to the accumulation of
BZDs and related active metabolites.42 BZD induce central nervous
system toxicity, generating symptoms such as anterograde amnesia,
sedation, drowsiness,motor impairment, inattentiveness, and ataxia.42
These effects are particularly higher in those living with dementia
where there are already processes such as neurodegeneration that
predispose to cognitive and functional impairment and other mani-
festations such as balance problems, delirium, and falls.
There are pharmacodynamic interactions between BZD and
antidepressant drugs which may increase the risk for adverse events.
For example, ADep such as Fluoxetine or Paroxetine reduces the
metabolism of some benzodiazepines43
A recent meta‐analysis in adults reported that participants in the
combined therapy BZD‐ADep presented at least one adverse effect
more often than participants who received antidepressants alone.44
It should be noted that in older adults, the risk of adverse effects
increases with the addition of a new medication, and even more when
both medications affect the same body system.17,45 This may explain
why BZD alone predicted fewer outcomes than BZD‐ADep.
F I GUR E 1 Prescription curve of the three groups during the 5
years' follow‐up. AD, Alzheimer’s disease; ADep, Antidepressants;
BZD, benzodiazepines; BZD‐ADep, simultaneous consume of
benzodiazepines and antidepressants; LBD, Lewy bodies dementia
TAB L E 1 Baseline characteristics of
the study sample
Total
n (%) or Mean ∓ SD LBD AD p‐value*
Age 75.30 ∓ 7.36 75.42 ∓ 6.90 75.20 ∓ 7.73 0.840
Sex ‐ ‐ ‐ <0.001
Women 77 (39.29) 38 (44.71) 81 (72.97)
Men 119 (60.71) 47 (55.29) 30 (27.03)
CIRS 5.83 ∓ 2.55 6.59 ∓ 2.55 5.33 ∓ 2.44 0.001
MMSE 23.67 ∓ 2.72 23.75 ∓ 3.19 23.61 ∓ 2.32 0.720
NPI total 19.52 ∓ 18.08 24.07 ∓ 18.81 16.04 ∓ 16.77 0.002
No BZD or ADep 107 (54.59) 44 (51.76) 63 (56.76) 0.430
Benzodiazepines 13 (6.63) 7 (8.24) 6 (5.41) 0.400
Antidepressants 48 (24.49) 18 (21.18) 30 (27.03) 0.490
Combined 19 (9.69) 9 (10.59) 10 (9.01) 0.054
Abbreviations: AD, Alzheimer's disease; ADep, Antidepressants; ADL, Activities of daily living; BZD,
Benzodizepines; CIRS, Cumulative Illness Rating Scale; LBD, Lewy bodies dementia; MMSE, Mini‐
mental state examination; NPI total, Total score of the Neuropsychiatric Inventory; Total, AD + DLB.
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Besides, the rate of BZD‐ADep prescriptions was higher than BZD
prescriptions alone, and it increased over time.
Thus, we speculate that the observed effects in this study on
functional decline are due to a sum of the BZD adverse effects, the
interaction BZD‐Adep effect, and neurodegeneration. The effect of
BZD alone was found only in the AD group, indicating that AD pa-
tients may be more susceptible to BZD's side effects than LBD, but,
the sample size of the LBD group was smaller than the AD group.
Previous studies of BZD plus ADep use have found a high
probability of combined use when one of the drugs have already been
prescribed,20,45,46 and with higher rates of prescription.46,47
Commonly these medications are prescribed without a clear
indication based on formal diagnosis, lack of a comprehensive geriatric
assessment, and inadequate adherence to updated recommendations
for prescription in older adultswith dementia. Research and consensus
panels have concluded that the prescription of all benzodiazepines to
older adults should be avoided for the treatment of insomnia, agita-
tion, or delirium.48 Despite this, the use of BZDs in older adults with or
without dementia, in nursing homes or living in community is still
prevalent,22,25,47 and tends to increase with the progression of de-
mentia. In this study, the number of people consuming BZD‐ADep had
increased from 9.69% in baseline to 39.39% in year 5.
Previous studies have reported BZD prescription as a possible
risk factor for dementia, as well as associations between BZD
prescription and greater cognitive decline.26,49,50 Despite this, in our
study, we did not find such association. This could be due to the
MMSE is language and memory dependent and thus less sensitive to
the earliest changes, especially in the LBD patients.51
Some ADep, such as tricyclics, have several adverse effects due
to their unspecific action on several receptors.45,52 However, these
medications have been progressively replaced by medications with a
better safety profile such as selective serotonin reuptake inhibitors.
In this study, ADep alone was not found to have any negative effect
on cognitive or functional trajectories.
These results suggest that the functional decline in patients with
dementia can be exacerbated by the negative effects of BZDs and
TAB L E 2 Association between medication group and functional decline across 5 years follow‐up in AD and LBD
Functional Decline
AD LBD Total
Variables Estimation Standard Error p‐value Estimation Standard Error p‐value Estimation Standard Error p‐value
No adjusted
BZD 0.233 0.093 0.0120 0.110 0.102 0.2810 0.207 0.069 0.0030
ADep 0.136 0.061 0.0270 −0.036 0.096 0.7070 0.074 0.054 0.1700
BZD‐Adep 0.252 0.062 0.0000 0.275 0.087 0.0020 0.280 0.052 0.0000
Time 0.316 0.036 0.0000 0.454 0.053 0.0000 0.369 0.030 0.0000
Time2 −0.007 0.006 0.2420 −0.027 0.010 0.0090 −0.015 0.005 0.0060
Intercept 1.544 0.067 0.0000 1.838 0.090 0.0000 1.671 0.055 0.0000
Adjusted
BZD 0.226 0.087 0.0090 0.011 0.105 0.9150 0.142 0.066 0.0320
ADep 0.076 0.057 0.1870 0.052 0.097 0.5930 0.073 0.050 0.1450
BZD‐Adep 0.165 0.058 0.0050 0.251 0.089 0.0050 0.218 0.049 0.0000
Time 0.241 0.034 0.0000 0.290 0.058 0.0000 0.259 0.030 0.0000
Time2 −0.015 0.006 0.0100 −0.023 0.011 0.0300 −0.020 0.005 0.0000
NPI Total 0.004 0.001 0.0000 0.006 0.002 0.0020 0.005 0.001 0.0000
Age 0.011 0.005 0.0300 0.014 0.008 0.0810 0.011 0.004 0.0100
Sex versus men −0.181 0.083 0.0290 −0.172 0.109 0.1150 −0.253 0.064 0.0000
CIRS 0.015 0.016 0.3420 −0.001 0.022 0.9760 0.020 0.013 0.1070
MMSE −0.037 0.004 0.0000 −0.041 0.006 0.0000 −0.040 0.003 0.0000
Intercept 1.596 0.368 0.0000 1.736 0.599 0.0040 1.712 0.320 0.0000
Notes: Females given as frequencies and (percentages), otherwise mean ± standard deviations. Time was evaluated with its quadratic and linear term.
Differences in gender assessed by Pearson's Chi‐square test, all other by Student's T‐test. Linear mixed models, NPI measured longitudinally and its
association with the functional trajectory.
Abbreviations: AD, Alzheimer's disease; ADep, Antidepressants; ADL, Activities of daily living; BZD, Benzodizepines; CIRS, Cumulative Illness Rating
Scale; LBD, Lewy bodies dementia; MMSE, Mini‐mental state examination; NPI total, Total score of the Neuropsychiatric Inventory.
p values < 0.05 are printed in bold.
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their combination with ADep. These adverse effects are independent
of neurodegeneration and can impair physical and mental functioning
leading to delirium, low blood pressure, falls, fractures, dependence,
hospitalizations. However, although we think this is the most likely
explanation, we cannot exclude the possibility of causality in the
opposite direction, that is, that antidepressants and BZD are pre-
scribed due to functional decline.
We are aware that our research may have a potential recruit-
ment bias because of referrals of primary care patients, which may
have led to an increased number of patients with complicated de-
mentia. However, GPs were encouraged to refer any patients with
suspected dementia, and patients were included from psychiatric,
neurologic, and geriatric clinics. Also confounding bias might be
present in that medication use is potentially associated with mor-
tality, which was the main reason for dropout in the study.
We did not differentiate between the type of antidepressant,
considering that tricyclics have a high rate of adverse effects.
However, in this study, the prescription of tricyclic ADep was found
at baseline only in one person. Likewise, for BZDs, all “Z” drugs were
put in this category (38.2% of the subjects consumed non-
benzodiazepine hypnotics (zopiklon = 12, zolpidem = 1). There is a
perception that nonbenzodiazepine hypnotics are safer than benzo-
diazepines, however recent studies suggest that this is inaccurate;
they tend to have a quicker onset and shorter duration of action but
produce similar side effects.18,53 There were a high dropout rate and
an expected high mortality, particularly in LBD, which may have
confounded the observed course of the studied outcomes.
Furthermore, fewer subjects consuming only BZD compared with
BZD‐ADep, and thus statistical power was higher for the BZD‐ADep
group. Initially, we aimed to study the effect of antipsychotics as well,
but this was not possible due to the low numbers (nine prescriptions
in total at baseline). Additionally, the specific indications for
prescriptions could not be determined. We are aware that the
indication for the prescription could influence the outcome.
For example, depression, anxiety, sleep disorders, delusions, halluci-
nations i.a. have been correlated with functional and cognitive decline
in dementia.41,54,55 However, we adjusted for total NPI to try to
control this interaction. Finally, the co‐prescription of other drugs
was not considered as a co‐variable. This may have influenced the
findings.
This study has several strengths, including long follow‐up time,
yearly assessments with structured instruments, and high complete-
ness of data. Outside of attrition because of death and dropouts,
persistency and reoccurrence analysis was achieved for mild to severe
dementia because of these advantages. There are few long‐term
studies assessing medication and daily functioning including LBD pa-
tients.18,56 Thediagnostic procedureswere rigorous, andhigh accuracy
has been demonstrated with neuropathological diagnosis.31 Future
studies with larger sample sizes are needed to better understand the
effect of psychotropics on function and cognition in people with
dementia.
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Scale; LBD, Lewy bodies dementia; MMSE, Mini‐mental state examination; NPI total, Total score of the Neuropsychiatric Inventory.
p values < 0.05 are printed in bold.
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